Search

everythinglearnresearchcommunity

for

Search:↓

Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.

The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.

Baldness (androgenic alopecia) could be a risk factor for prostate cancer.

Higher BMI is linked to a lower risk of non-aggressive prostate cancer and a higher risk of aggressive prostate cancer.

ERG increases SOX9, promoting prostate cancer growth and invasion.

Prostate cancer was a major health issue in 2009, especially for Black men, and targeting the 5alpha-reductase enzyme could help in its prevention and treatment.

The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.

Urologic diseases and treatments in older men can negatively affect fertility, and doctors should talk to patients about this.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.

Early hair loss may increase the risk of prostate cancer, especially in African American men and those with frontal baldness.

Eating more omega-3 and less omega-6 fatty acids may lower the risk of developing prostate cancer.

Men who start losing hair at 20 may have a higher chance of getting prostate cancer later.

CEC levels may be a useful marker for predicting prostate cancer progression.

Early baldness increases prostate cancer risk, radiotherapy and surgery have similar second cancer rates, and ALA may reduce prostate cancer risk.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

Serum triglyceride levels are not linked to prostate cancer risk.

Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.

Dicentrine reduced heart disease risk factors in rats, T-588 protected mice brains without side effects, Provir blocked herpes virus and lessened mouse symptoms, and LY191704 could treat hair loss and prostate issues.

Flutamide rarely causes liver toxicity in prostate cancer patients.

Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.

Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.

The conclusion is that there might be a link between certain types of baldness and prostate cancer, which could be due to shared hormonal pathways.

New treatments are making advanced prostate cancer management more complex but also more hopeful.

5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.

Melatonin receptors, found in many body parts, can help treat various diseases like depression and diabetes due to their effects on inflammation, tumor progression, sleep disorders, and body mass regulation.

Black ethnicity, prior PSA tests, enlarged prostate, and family history increase prostate cancer risk; Asian ethnicity, obesity, smoking, diabetes, and less sexual activity or no children decrease risk.

New method finds genetic links between Type 2 Diabetes and Prostate Cancer not seen before.

Organoids created from stem cells are used to model diseases, test drugs, and develop personalized and regenerative medicine.